Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.

McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.

Osteoporos Int. 2013 Jan;24(1):301-10. doi: 10.1007/s00198-012-2175-7. Epub 2012 Oct 19.

PMID:
23079690
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.

McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.

Osteoporos Int. 2012 Jan;23(1):267-76. doi: 10.1007/s00198-011-1791-y. Epub 2011 Sep 27.

PMID:
21947137
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.

Osteoporos Int. 2013 Jan;24(1):293-9. doi: 10.1007/s00198-012-2056-0. Epub 2012 Jun 30.

PMID:
22752050
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.

Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR.

Osteoporos Int. 2008 Jul;19(7):1039-45. Epub 2007 Dec 18.

PMID:
18087660
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.

Bone. 2008 Jan;42(1):36-42. Epub 2007 Sep 8.

PMID:
17920005
[PubMed - indexed for MEDLINE]
6.

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.

Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.

J Bone Miner Res. 2009 Apr;24(4):719-25. doi: 10.1359/jbmr.081214.

PMID:
19049326
[PubMed - indexed for MEDLINE]
7.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
8.

Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.

Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T.

Bone. 2014 Feb;59:44-52. doi: 10.1016/j.bone.2013.10.017. Epub 2013 Oct 29.

PMID:
24184313
[PubMed - indexed for MEDLINE]
Free Article
9.

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.

Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD.

Osteoporos Int. 2009 Nov;20(11):1895-902. doi: 10.1007/s00198-009-0893-2. Epub 2009 Mar 19.

PMID:
19296144
[PubMed - indexed for MEDLINE]
10.

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.

Clin Ther. 2009 Feb;31(2):272-85. doi: 10.1016/j.clinthera.2009.02.012.

PMID:
19302900
[PubMed - indexed for MEDLINE]
11.

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.

Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.

Bone. 2012 Sep;51(3):383-8. doi: 10.1016/j.bone.2012.06.016. Epub 2012 Jun 30.

PMID:
22750403
[PubMed - indexed for MEDLINE]
12.

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.

Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP.

Curr Med Res Opin. 2004 May;20(5):757-64. Erratum in: Curr Med Res Opin. 2004 Oct;20(10):1690.

PMID:
15140343
[PubMed - indexed for MEDLINE]
13.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
[PubMed - indexed for MEDLINE]
14.

A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Benhamou CL, Man Z, Tlustochowicz W, Zanchetta JR, Eusebio R, Balske AM, Matzkin E, Olszynski WP, Recker R, Delmas PD.

Calcif Tissue Int. 2013 Jan;92(1):59-67. doi: 10.1007/s00223-012-9668-4. Epub 2012 Nov 13.

PMID:
23150144
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.

Ilter E, Karalok H, Tufekci EC, Batur O.

Climacteric. 2006 Apr;9(2):129-34.

PMID:
16698659
[PubMed - indexed for MEDLINE]
16.

Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.

Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y; Risedronate Phase III Research Group.

J Bone Miner Metab. 2006;24(5):405-13.

PMID:
16937274
[PubMed - indexed for MEDLINE]
17.

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.

Osteoporos Int. 2003 May;14(3):225-34. Epub 2003 Apr 10.

PMID:
12730746
[PubMed - indexed for MEDLINE]
18.

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.

Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.

Calcif Tissue Int. 2002 Aug;71(2):103-11. Epub 2002 Jun 27.

PMID:
12085156
[PubMed - indexed for MEDLINE]
19.

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E.

Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review.

PMID:
19835464
[PubMed - indexed for MEDLINE]
20.

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY.

Osteoporos Int. 1997;7(5):488-95.

PMID:
9425508
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk